ScholarIQanswers from OpenAlex & ORCID
Charlie Gourley
ResearcherPublications, citations & collaboration network
Charlie Gourley is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Charlie Gourley have?
ScholarIQindexed works
Charlie Gourley has 462 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Charlie Gourley have?
ScholarIQcitation count
Charlie Gourley has 24,840 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Charlie Gourley?
ScholarIQh-index
Charlie Gourley has an h-index of 60 in OpenAlex.
What is the i10-index of Charlie Gourley?
ScholarIQi10-index
Charlie Gourley has an i10-index of 166 in OpenAlex.
What is the ORCID of Charlie Gourley?
ScholarIQorcid
The ORCID for Charlie Gourley is on the source record.
What is the OpenAlex record for Charlie Gourley?
ScholarIQopenalex
The OpenAlex for Charlie Gourley is on the source record.
What are the most-cited papers on Charlie Gourley?
ScholarIQmost cited works
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A. Ledermann, Éric Pujade-Lauraine, Gunnar B. Kristensen, Mark S. Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder, Andreas du Bois, Jalid Sehouli, Rainer Kimmig, Anne Stähle, Fiona Collinson, Sharadah Essapen, Charlie Gourley, Alain Lortholary, Frédèric Selle, Mansoor R. Mirza, Arto Leminen, Marie Plante, Dan Stark, Wendi Qian, Mahesh Parmar, Amit M. Oza
Epithelial ovarian cancer
Stéphanie Lheureux, Charlie Gourley, Ignace Vergote, Amit M. Oza
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedländer, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Euan Macpherson, Claire Watkins, James Carmichael, Ursula A. Matulonis
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, John McNamara, Elizabeth Lowe, Mei-Lin Ah-See, Kathleen N. Moore, on behalf of the SOLO1 Investigators